| Studie / Autor | Pat. | Random | LRFS | FFBF | Rektum Tox. |
| MGH-Studie (3) | 202, T3/4 | RT 67,2 Gy | 78% | 61% | 8 |
| RT 75,6Gy, Protonen-Boost | 88% | 80% | 17 | ||
| MDACC-Studie (1,2) | 305, T1-3 | RT 70Gy | 82% | 50% | 13 |
| RT 78Gy | 93% | 73% | 26 | ||
| Dutch-Trial (4,5) | 664, T1-3 | RT 68Gy | 76% | 54% | 27 |
| RT 78Gy | 76% | 64% | 23 |
LRFS: Local recurence free surv1val, Überleben ohne Lokalrezidiv
FFBF: free from biochemical failor, Überleben ohne PSA-Rezidiv
Rektum Tox: Rektum Toxizität > Grad 1
Dearnaley DP, Hall E, Lawrence D, et al.:
Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects.
Br J Cancer 2005;92:488–498
2.) Pollack A, Zagars GK, Starkschall G, et al.:
Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial.
Int J Radiat Oncol Biol Phys 2002;53:1097–1105
3.) MGH: Massachusetts General Hospital
Shipley WU, Verhey LJ, Munzenrider JE, et al.:
Advanced prostate cancer: The results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone.
Int J Radiat Oncol Biol Phys. 1995;32:3–12
4.) Dutch Trial
Kuban D, Tucker S, Dong L, et al.:
Long-term results of a randomized dose escalation trial for prostate cancer.
Int J Radiat Oncol Biol Phys 2006;66:8–9
5.) Peeters ST, Heemsbergen WD, Koper PC, et al.:
Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy.
J Clin Oncol 2006;24:1990–1996
